Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance
- PMID: 24814823
- DOI: 10.1016/j.coviro.2014.04.005
Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance
Abstract
Hepatitis B virus (HBV) polymerase and human immunodeficiency virus (HIV) reverse transcriptase are structurally related. However, the HBV enzyme has a protein priming activity absent in the HIV enzyme. Approved nucleoside/nucleotide inhibitors of the HBV polymerase include lamivudine, adefovir, telbivudine, entecavir and tenofovir. Although most of them target DNA elongation, guanosine and adenosine analogs (e.g. entecavir and tenofovir, respectively) also impair protein priming. Major mutational patterns conferring nucleoside/nucleotide analog resistance include the combinations rtL180M/rtM204(I/V) (for lamivudine, entecavir, telbivudine and clevudine) and rtA181V/rtN236T (for adefovir and tenofovir). However, development of drug resistance is very slow for entecavir and tenofovir. Novel nucleoside/nucleotide analogs in advanced clinical trials include phosphonates similar to adefovir or tenofovir, and new tenofovir derivatives with improved pharmacological properties.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.Antiviral Res. 2009 Feb;81(2):147-55. doi: 10.1016/j.antiviral.2008.10.008. Epub 2008 Nov 24. Antiviral Res. 2009. PMID: 19028525
-
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.Antivir Ther. 2007;12(3):355-62. Antivir Ther. 2007. PMID: 17591025
-
The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.Antiviral Res. 2011 Nov;92(2):271-6. doi: 10.1016/j.antiviral.2011.08.012. Epub 2011 Aug 18. Antiviral Res. 2011. PMID: 21871497
-
Treatment of chronic hepatitis B: Evolution over two decades.J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:138-43. doi: 10.1111/j.1440-1746.2010.06545.x. J Gastroenterol Hepatol. 2011. PMID: 21199525 Review.
-
Resistance issues in treating chronic hepatitis B.Future Microbiol. 2008 Oct;3(5):525-38. doi: 10.2217/17460913.3.5.525. Future Microbiol. 2008. PMID: 18811237 Review.
Cited by
-
New horizon for radical cure of chronic hepatitis B virus infection.World J Hepatol. 2016 Jul 28;8(21):863-73. doi: 10.4254/wjh.v8.i21.863. World J Hepatol. 2016. PMID: 27478536 Free PMC article.
-
Emerging antiviral resistant strains of influenza A and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) complex.Virol J. 2014 Sep 16;11:167. doi: 10.1186/1743-422X-11-167. Virol J. 2014. PMID: 25228366 Free PMC article. Review.
-
Induction of hepatitis B core protein aggregation targeting an unconventional binding site.Elife. 2025 Mar 26;13:RP98827. doi: 10.7554/eLife.98827. Elife. 2025. PMID: 40135596 Free PMC article.
-
Synthesis and evaluation of the anti-hepatitis B virus activity of 4'-Azido-thymidine analogs and 4'-Azido-2'-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.Nucleosides Nucleotides Nucleic Acids. 2020;39(4):518-529. doi: 10.1080/15257770.2019.1664749. Epub 2019 Sep 12. Nucleosides Nucleotides Nucleic Acids. 2020. PMID: 31514570 Free PMC article.
-
Chronic hepatitis B: A wave of new therapies on the horizon.Antiviral Res. 2015 Sep;121:69-81. doi: 10.1016/j.antiviral.2015.06.014. Epub 2015 Jun 22. Antiviral Res. 2015. PMID: 26112647 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources